

JC20 Rec'd PCT/PE 0 7 JUL 2005

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PTC)		Complete it Known		
				Application Number	Luds/igDd 1447	
INFO	RMATION	DIS	CLOSURE	Filing Date	July 7,2005	
STAT	EMENT B	Y AF	PLICANT	First Named Inventor	Valerie AUTIER et al.	
• • • • • • • • • • • • • • • • • • • •				Group Art Unit	Unassigned	
	(use as many she	ets es	necessary)	Examiner Name	Unassigned	
Sheet	1	of	2	Attorney Docket Number	MERCK-3029	

U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.1	U.S. Petent Docume	Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
and.	, 1	5877193		Cesura Andrea et al.	March 2, 1999		
au.	1. 2	6143787		Kergoat Micheline et al.	November 7, 2000		
an	3	2003166689			September 4, 2003		
			 				
		*************************************	1.				

				FORE	IGN PATENT DOCUMEN	ITS		,
Examiner Initials*	Cits No.1	Office ³	Foreign Patent Docum Number*	Ment Kind Code ^s (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	τ•
anh	4	EP	0885869		Japan Tobacco Inc	December 23, 1998		
arl) 5	wo	0190092		Biovitrum AB	November 29, 2001		Equv to cite 3
				1				
				+				
				+				

	\			
Examiner Signature	ia Hugher	Date Considered	08/03/	12007

EXAMINER: Initial if peter inco considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.



JC20 Rec'd PCT/F 0 7 JUL 2005

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for	r form 1449A/P	то		Complete if Kaoun I. O.Z		
			001105	Application Number	Unasing ord 1472	
			OSURE.	Filing Date	July 7, 2005	
STATE	EMENT I	BY APP	LICANT	First Named Inventor	Valerie AUTIER et al.	
				Group Art Unit	Unassigned	
(u	se as many s	heets as nec	essary)	Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	MERCK-3029	

		NON PATENT LITERATURE DOCUMENTS	.,
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
an	6	NAOKI ET AL.: "A novel enhancer of insulinotrophic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta cells via a new cellular mechanism" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 297, no. 3, 2001, pages 953-960 XP002263095.	
ar or	7	OHTA et al.: "JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 367, 1999, pages 91-99, XP002263096.	
are	, 8	ESTOPINAN GARCIA V et al: "Perspectives of the immunosuppressive treatment for the prevention of diabetes mellitus type I" ANALES DE MEDICINA INTERNA 1992 SPAIN, vol. 9, no. 10, 1992, pages 471-472, XP009031857	
an	9	MANDRUP-POULSEN T R ET AL: Cyclosporin immunosuppression induces clinical remission and improved 'betal-cell function in newly diagnosed insulin-dependent diabetecs: A national and international multicentre study" UGESKRIFT FOR LAEGER 1990 DENMARK, vol. 152, no. 27, 1990, pages 1963-1969, XP009031858	
anh	10	CONNICK ET AL.: "The role of kynurenines in diabetes mellitus" MEDICAL HYPOTHESES, vol.; 18, no, 4, 1985, pages 371-376, XP009021813	
_			
	<u> </u>		

Examiner Date Considered	
Signature / Considered	08/03/2007

EXAMINER: Initial irreference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.